FibroBiologics, Inc. (FBLG): Total Liabilities
$3.46M
As of 2025-12-31
$3.29M
As of 2026-06-30
-26.8%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.46M | -74.7% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $13.71M | +29.7% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $10.57M | +19.8% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $8.82M | n/a | 2024-02-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| FibroBiologics, Inc. (FBLG) | 2025-12-31 | $3.46M | -74.7% |
| MAIA Biotechnology, Inc. (MAIA) | 2025-12-31 | $7.33M | +12.4% |
| Cocrystal Pharma, Inc. (COCP) | 2025-12-31 | $3.38M | -14.0% |
| Kala Bio, Inc. (KALA) | 2025-12-31 | $2.49M | -94.2% |
| Indaptus Therapeutics, Inc. (INDP) | 2024-12-31 | $3.39M | +19.2% |
| Soligenix, Inc. (SNGX) | 2025-12-31 | $3.94M | -18.7% |
| Medicus Pharma Ltd. (MDCX) | 2025-12-31 | $10.02M | +299.0% |
| Oragenics Inc (OGEN) | 2025-12-31 | $1.79M | +6.1% |
| ProMIS Neurosciences Inc. (PMN) | 2025-12-31 | $10.44M | +330.9% |
Compare FBLG, MAIA, COCP, KALA side by side · Screen every company in Pharmaceutical Preparations ↗